Full Press Release Details
record monthly Travelan sales
Melbourne, Australia, September 13, 2023: Immuron
Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record
monthly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health immune supplement Travelan .
Immuron previously reported (August 9, 2023)
that short term stock outages of Travelan in some wholesalers and pharmacies in the June 2023 quarter was resolved following
receipt of GMP Clearance from the Therapeutic Goods Administration (TGA). Immuron has since supplied product to wholesalers who in turn
have supplied retail pharmacies.
increased by 7984% in August 2023 to AUD $1.18 M, compared to AUD $14,581 in August 2022. This increase partially reflects 3 months
of backorders accrued while awaiting GMP Clearance from the TGA.
Immuron anticipates continued demand for replenishment
of Travelan as retail pharmacies sell to consumers. Short term resident returns in July 2023 were 48% higher than July
2022 and approaching pre-pandemic levels (89% of April 2019)1.
Australian Bureau of Statistics resident returns
- short term compares resident returns each month by destination country. Analysis is undertaken on short-term trips (less than
one year). Indonesia was the most popular destination country, accounting for 14% of all resident returns.1
Immuron previously reported (July 5, 2023) that it had shipped inventory to Amazon for launch in USA. The Amazon launch has been progressing
well. Sales via Amazon in August exceeded those to our largest B2B customer, Passport Health. We are now entering the low travel season
in USA. Immuron anticipates sales to grow strongly closer to the peak spring / summer travel period.
This release has been authorised by
the directors of Immuron Limited.
Chief Executive Officer
is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers' diarrhea,
a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce.
Travelan is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when
taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers' diarrhea.
In Australia, Travelan is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated
to reduce the risk of Travelers' Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada,
Travelan is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers'
Diarrhea. In the U.S., Travelan is sold as a dietary supplement for digestive tract protection.
diarrhea is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping,
bloating, and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing
a dominant causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections
with Salmonella spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are
often confused with travelers' diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable.
Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.
more information visit: http://www.immuron.com
FORWARD-LOOKING STATEMENTS:
may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to
our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements
are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business,
operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently
anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic
agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting
and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers;
our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional
funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings.
We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained
herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is
based, except as required by law.